Kailera Therapeutics is advancing a pipeline of weight loss medicines that mirror that of Eli Lilly’s: an injectable GLP-1/GIP dual agonist like Zepbound, an oral GLP-1 like Foundayo and a triple-G ...

Drugs that bind to and activate the receptors for the hormones GLP-1 and GIP are effective in the treatment of obesity and diabetes. Surprisingly, active substances are currently being developed that ...

Please provide your email address to receive an email when new articles are posted on . An investigational GLP-1/GIP dual agonist induced up to 7.8% weight loss at 28 days in a phase 1 study.

The MarketWatch News Department was not involved in the creation of this content. Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau ...

If you live with obesity or type 2 diabetes, your doctor may have talked to you about GIP/GLP-1 agonist medications, such as tirzepatide (Mounjaro or Zepbound), which may help you lose weight. And ...

BERLIN — A novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist combined into a single drug (LY3298176, Lilly), dubbed a "twincretin," ...

Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro ...

Research is looking for ways to minimize muscle loss from GLP-1 drugs taken to treat obesity. Iuliia Burmistrova/Getty Images New research to be presented at the European Congress on Obesity (ECO 2025 ...

SAN DIEGO, Nov. 1, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...